Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

XL-protein GmbH. (1/9/18). "Press Release: Horizon Pharma plc and XL-protein GmbH Have Entered Into a Collaboration Agreement on a Potential Next-Generation Biologic for Uncontrolled Gout Using PASylation® Technology". Freising.

Organisations Organisation XL-protein GmbH (XLp)
  Organisation 2 Horizon Pharma plc
  Group Horizon Pharma (Group)
Products Product PASylation® technology
  Product 2 biopharmaceutical
Persons Person Schalper, Claus (XL-protein 201410 Managing Director (CEO) before Pieris 201101 CFO)
  Person 2 Skerra, Arne (XL-protein GmbH 201104 Managing Director)
     


Horizon Pharma plc (NASDAQ:HZNP) yesterday announced that it has entered into a collaboration agreement with XL-protein GmbH to identify clinical-stage program candidates that could use PASylation technology to construct a next-generation gout biologic.

PASylation technology is a biological alternative to synthetic PEGylation and is intended to extend both the half-life of uricase and the duration of treatment for people living with uncontrolled gout, and also has the potential for subcutaneous dosing.

If the agreement yields a clinical-stage candidate, Horizon Pharma will have the right to license the candidate.


About XL-protein GmbH

XL-protein is a German biotech company commercializing its ground-breaking PASylation® technology, which enables the design of biopharmaceuticals with extended plasma half-life and enhanced action. Based on a strong proprietary technology position, XL-protein focuses at the preclinical as well as clinical development of PASylated proteins in diverse disease areas. XL-protein is engaged in a growing number of partnerships with international pharmaceutical and biotech companies at various levels. For more information, please visit www.xl-protein.com


XL-protein Contacts:

Business:
Claus Schalper
CEO / Managing Director
+49 8161 53730 90

Technology:
Arne Skerra
Cofounder and Chairman of the Board
+49 8161 53730 91

   
Record changed: 2018-01-18

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px

More documents for XL-protein GmbH (XLp)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top